Haihe Biopharma Co., a Chinese pharmaceutical company specialized in innovative oncology drugs, has secured a US$146.6 million new round of investment led by China-focused private equity firm Huagai Capital, said Haihe Biopharma in a statement released on Monday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?